John A Viator, Marc Hazur, Andrea Sajewski, Ahmad Tarhini, Martin E Sanders, Robert H Edgar
{"title":"晚期患者循环黑色素瘤细胞的光声检测。","authors":"John A Viator, Marc Hazur, Andrea Sajewski, Ahmad Tarhini, Martin E Sanders, Robert H Edgar","doi":"10.1142/s1793545820500236","DOIUrl":null,"url":null,"abstract":"<p><p>Melanoma is the deadliest skin cancer and is responsible for over 7000 deaths in the US annually. The spread of cancer, or metastasis, is responsible for these deaths, as secondary tumors interrupt normal organ function. Circulating tumor cells, or those cells that spread throughout the body from the primary tumor, are thought to be responsible for metastasis. We developed an optical method, photoacoustic flow cytometry, in order to detect and enumerate circulating melanoma cells (CMCs) from blood samples of patients. We tested the blood of Stage IV melanoma patients to show the ability of the photoacoustic flow cytometer to detect these rare cells in blood. We then tested the system on archived blood samples from Stage III melanoma patients with known outcomes to determine if detection of CMCs can predict future metastasis. We detected between 0 and 66 CMCs in Stage IV patients. For the Stage III study, we found that of those samples with CMCs, 2 remained disease free and 5 developed metastasis. Of those without CMCs, 6 remained disease free and 1 developed metastasis. We believe that photoacoustic detection of CMCs provides valuable information for the prediction of metastasis and we postulate a system for more accurate prognosis.</p>","PeriodicalId":16248,"journal":{"name":"Journal of Innovative Optical Health Sciences","volume":"13 6","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218985/pdf/nihms-1606057.pdf","citationCount":"4","resultStr":"{\"title\":\"Photoacoustic detection of circulating melanoma cells in late stage patients.\",\"authors\":\"John A Viator, Marc Hazur, Andrea Sajewski, Ahmad Tarhini, Martin E Sanders, Robert H Edgar\",\"doi\":\"10.1142/s1793545820500236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Melanoma is the deadliest skin cancer and is responsible for over 7000 deaths in the US annually. The spread of cancer, or metastasis, is responsible for these deaths, as secondary tumors interrupt normal organ function. Circulating tumor cells, or those cells that spread throughout the body from the primary tumor, are thought to be responsible for metastasis. We developed an optical method, photoacoustic flow cytometry, in order to detect and enumerate circulating melanoma cells (CMCs) from blood samples of patients. We tested the blood of Stage IV melanoma patients to show the ability of the photoacoustic flow cytometer to detect these rare cells in blood. We then tested the system on archived blood samples from Stage III melanoma patients with known outcomes to determine if detection of CMCs can predict future metastasis. We detected between 0 and 66 CMCs in Stage IV patients. For the Stage III study, we found that of those samples with CMCs, 2 remained disease free and 5 developed metastasis. Of those without CMCs, 6 remained disease free and 1 developed metastasis. We believe that photoacoustic detection of CMCs provides valuable information for the prediction of metastasis and we postulate a system for more accurate prognosis.</p>\",\"PeriodicalId\":16248,\"journal\":{\"name\":\"Journal of Innovative Optical Health Sciences\",\"volume\":\"13 6\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2020-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218985/pdf/nihms-1606057.pdf\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Innovative Optical Health Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1142/s1793545820500236\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/8/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPTICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Innovative Optical Health Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1142/s1793545820500236","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/8/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPTICS","Score":null,"Total":0}
Photoacoustic detection of circulating melanoma cells in late stage patients.
Melanoma is the deadliest skin cancer and is responsible for over 7000 deaths in the US annually. The spread of cancer, or metastasis, is responsible for these deaths, as secondary tumors interrupt normal organ function. Circulating tumor cells, or those cells that spread throughout the body from the primary tumor, are thought to be responsible for metastasis. We developed an optical method, photoacoustic flow cytometry, in order to detect and enumerate circulating melanoma cells (CMCs) from blood samples of patients. We tested the blood of Stage IV melanoma patients to show the ability of the photoacoustic flow cytometer to detect these rare cells in blood. We then tested the system on archived blood samples from Stage III melanoma patients with known outcomes to determine if detection of CMCs can predict future metastasis. We detected between 0 and 66 CMCs in Stage IV patients. For the Stage III study, we found that of those samples with CMCs, 2 remained disease free and 5 developed metastasis. Of those without CMCs, 6 remained disease free and 1 developed metastasis. We believe that photoacoustic detection of CMCs provides valuable information for the prediction of metastasis and we postulate a system for more accurate prognosis.
期刊介绍:
JIOHS serves as an international forum for the publication of the latest developments in all areas of photonics in biology and medicine. JIOHS will consider for publication original papers in all disciplines of photonics in biology and medicine, including but not limited to:
-Photonic therapeutics and diagnostics-
Optical clinical technologies and systems-
Tissue optics-
Laser-tissue interaction and tissue engineering-
Biomedical spectroscopy-
Advanced microscopy and imaging-
Nanobiophotonics and optical molecular imaging-
Multimodal and hybrid biomedical imaging-
Micro/nanofabrication-
Medical microsystems-
Optical coherence tomography-
Photodynamic therapy.
JIOHS provides a vehicle to help professionals, graduates, engineers, academics and researchers working in the field of intelligent photonics in biology and medicine to disseminate information on the state-of-the-art technique.